Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 7/2015

01-07-2015 | Brief Report

Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis

Authors: Kuttipurath Kandi Roshique, Vinod Ravindran

Published in: Clinical Rheumatology | Issue 7/2015

Login to get access

Abstract

Biosimilar usage in rheumatology is set to increase over the next few years. This study reports the efficacy and toxicity of a rituximab biosimilar in biologic naïve patients with active rheumatoid arthritis who had inadequately responded to methotrexate. In 21 patients, over a follow-up period of 36 months, it demonstrated prolonged benefit in a majority (10 in remission with disease activity score 28 (DAS28) erythrocyte sedimentation rate (ESR) <2.6 and 9 in low disease activity state with DAS28 ESR between 3.2 and 2.6) and was well tolerated.
Literature
1.
Emery P, Fleischmann R, Filipowicz-Sosnowska A et al (2006) DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose ranging trial. Arthritis Rheum 54:1390–1400PubMedCrossRef
2.
Cohen SB, Emery P, Greenwald MW et al (2006) REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793–2806PubMedCrossRef
3.
Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581PubMedCrossRef
4.
Rubbert-Roth A, Tak PP, Zerbini C et al (2010) MIRROR Trial Investigators. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 49:1683–1693CrossRef
5.
Emery P, Deodhar A, Rigby WF et al (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE). Ann Rheum Dis 69:1629–1635PubMedCentralPubMedCrossRef
6.
Tak PP, Rigby W, Rubbert-Roth A et al (2012) Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 71:351–357PubMedCentralPubMedCrossRef
7.
Keystone EJ, Cohen SB, Emery P et al (2012) Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol 39:2238–2246PubMedCrossRef
8.
De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R, MIRA Study Group (2014) Long-term follow-up of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in rheumatoid arthritis registry. J Rheumatol 41:1761–1765PubMedCrossRef
9.
10.
Beck A, Reichert JM (2013) Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 5:621–623PubMedCentralPubMedCrossRef
11.
12.
Roy PS, John S, Karankal S et al (2013) Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: a retrospective analysis. Indian J Med Paediatr Oncol 34:292–298PubMedCentralPubMedCrossRef
13.
Rawat R, Kapoor S, Garg S et al (2009) Efficacy and safety of a biosimilar-rituximab (Reditux™) in rheumatoid arthritis. Indian J Rheumatol 4(Suppl 1):S18–S19CrossRef
14.
Prevoo ML, van’t Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef
15.
Kumar A, Malaviya AN, Pandhi A, Singh R (2002) Validation of an Indian version of the health assessment questionnaire in patients with rheumatoid arthritis. Rheumatology (Oxford) 41:1457–1459CrossRef
16.
Dörner T, Strand V, Castañeda-Hernández G et al (2013) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 72:322–328PubMedCrossRef
17.
Scheinberg MA, Azevedo VF (2014) Biosimilars in rheumatology: perspective and concerns. Rheumatology (Oxford) 53:389–390CrossRef
18.
Park W, Hrycaj P, Jeka S et al (2013) A randomised, double-blind, multicenter, parallel-group, prospective study comparing the pharmacokinetics, safety and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72:1605–1612PubMedCentralPubMedCrossRef
19.
Dae Hyun Yoo DH, Hrycaj P, Miranda P et al (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72:1613–1620PubMedCentralPubMedCrossRef
20.
21.
Jani M, Hirani N, Matteson EL, Dixon WG (2014) The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol 10:284–294PubMedCrossRef
22.
Maher LV, Wilson JG (2006) Successful treatment of rheumatoid vasculitis-associated foot drop with rituximab. Rheumatology (Oxford) 45:1450–1451CrossRef
Metadata
Title
Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis
Authors
Kuttipurath Kandi Roshique
Vinod Ravindran
Publication date
01-07-2015
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 7/2015
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-015-2980-4

Other articles of this Issue 7/2015

Clinical Rheumatology 7/2015 Go to the issue

Original Article

Detection of bone erosions in early rheumatoid arthritis: 3D ultrasonography versus computed tomography

Original Article

FRAX fracture risk in women with a recent fracture of the distal forearm: agreement between assessments with and without bone mineral density and impact of measurement side in the individual patient

Case Based Review

Anakinra treatment in drug-resistant Behcet’s disease: a case series

Original Article

The relationship between disease activity and depression and sleep quality in Behçet’s disease patients

Brief Report

Chikungunya infection in the general population and in patients with rheumatoid arthritis on biological therapy

Editorial

Should all rheumatologists study musculoskeletal anatomy?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits